MEM 3454: Phase IIb started

Roche disclosed that last quarter it began a placebo-controlled Phase IIb trial to evaluate 1, 5 or 10 mg oral RG3487 as an add-on therapy to Aricept in 360 patients. Roche acquired the compound thro...